Skip to main content

Table 2 CEA, CYFRA 21-1 and NSE variation according to response to nivolumab

From: The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients

 

Median (%)

Range (%)

p-value

CEA

No responder

+ 31

− 79; + 498

0.005

Responder

− 9

− 92: + 88

 

CYFRA21-1

No responder

+ 72

− 62; + 508

< 0.001

Responder

− 37

− 98; + 2220

 

NSE

No responder

+ 20

− 64; + 182

0.012

Responder

− 14

− 79; + 71

 
Back to article page

Journal of Translational Medicine

ISSN: 1479-5876

Contact us